Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other financing activities (2021 - 2024)

Vivos Therapeutics' Other financing activities history spans 3 years, with the latest figure at $500000.0 for Q4 2024.

  • Quarterly results put Other financing activities at $500000.0 for Q4 2024, up 15.74% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (down 28.69% YoY), and the annual figure for FY2025 was $837000.0, down 38.5%.
  • Other financing activities for Q4 2024 was $500000.0 at Vivos Therapeutics, down from $509000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $645000.0 in Q1 2023 to a low of $4000.0 in Q3 2021.
  • The 3-year median for Other financing activities is $432000.0 (2023), against an average of $356571.4.
  • Peak annual rise in Other financing activities hit 15.74% in 2024, while the deepest fall reached 52.56% in 2024.
  • Year by year, Other financing activities stood at $4000.0 in 2021, then surged by 10700.0% to $432000.0 in 2023, then grew by 15.74% to $500000.0 in 2024.
  • According to Business Quant data, Other financing activities over the past three periods came in at $500000.0, $509000.0, and $100000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.